GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.
Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...
The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...
Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.
EC has granted marketing authorisation to BridgeBio Pharma’s acoramidis under the Beyonttra brand name for treating ATTR-CM.
Health Canada has approved MSD’s anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...
Being realistic, responsive and transparent is key in engaging unresponsive and underperforming clinical trial sites; that ...